We sought to examine, via Phosphorus-31 magnetic resonance spectroscopy (31P-MRS) in a case-control design, whether bioenergetic deficits in autism spectrum disorders extend to the brain and muscle. Six cases with autism spectrum disorder with suspected mitochondrial dysfunction (age 6-18 years) and 6 age/sex-matched controls underwent 31P magnetic resonance spectroscopy. The outcomes of focus were muscle resting phosphocreatine and intracellular pH as well as postexercise phosphocreatine recovery time constant and frontal brain phosphocreatine. Intracellular muscle pH was lower in each autism spectrum disorder case than their matched control (6/6, P = .03; P = .0048, paired t test). Muscle phosphocreatine (5/6), brain phosphocreatine (3/4), and muscle phosphocreatine recovery time constant (3/3) trends were in the predicted direction (not all participants completed each). This study introduces 31P magnetic resonance spectroscopy as a noninvasive tool for assessment of mitochondrial function in autism spectrum disorder enabling bioenergetic assessment in brain and provides preliminary evidence suggesting that bioenergetic defects in cases with autism spectrum disorder are present in muscle and may extend to brain.
MinshewNJGoldsteinGDombrowskiSMPanchalingamKPettegrewJW. A preliminary 31P MRS study of autism: evidence for undersynthesis and increased degradation of brain membranes. Biol Psychiatry. 1993;33:762–773.
2.
GiuliviCZhangY-FOmanska-KlusckA. Mitochondrial dysfunction in autism. JAMA. 2010;304:2389–2396.
3.
FilipekPAJuranekJSmithM. Mitochondrial dysfunction in autistic patients with 15q inverted duplication. Ann Neurol. 2003;53:801–804.
4.
PonsRAndreuALCheccarelliN. Mitochondrial DNA abnormalities and autistic spectrum disorders. J Pediatr. 2004;144:81–85.
5.
PolingJSFryeREShoffnerJZimmermanAW. Developmental regression and mitochondrial dysfunction in a child with autism. J Child Neurol. 2006;21:170–172.
6.
FehmHLKernWPetersA. The selfish brain: competition for energy resources. Prog Brain Res. 2006;153:129–140.
7.
ShulmanRGRothmanDLBeharKLHyderF. Energetic basis of brain activity: implications for neuroimaging. Trends Neurosci. 2004;27:489–495.
8.
LodiRIottiSScorolliL. The use of phosphorus magnetic resonance spectroscopy to study in vivo the effect of coenzyme Q10 treatment in retinitis pigmentosa. Mol Aspects Med. 1994;15(suppl):s221–s230.
9.
BarbiroliBFrassinetiCMartinelliP. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cell Mol Biol (Noisy-le-grand). 1997;43:741–749.
10.
BarbiroliBlottiSLodiR.Improved brain and muscle mitochondrial respiration with CoQ. An in vivo study by 31P-MR spectroscopy in patients with mitochondrial cytopathies. Biofactors. 1999;9:253–260.
11.
LottiSLodiRFrassinetiCZaniolPBarbiroliB.In vivo assessment of mitochondrial functionality in human gastrocnemius muscle by 31P MRS. The role of pH in the evaluation of phosphocreatine and inorganic phosphate recoveries from exercise. NMR Biomed. 1993;6:248–253.
12.
TaylorDJBorePJStylesPGadianDGRaddaGK. Bioenergetics of intact human muscle. A 31P nuclear magnetic resonance study. Mol Biol Med. 1983;1:77–94.
13.
KempGJTaylorDJRaddaGK. Control of phosphocreatine resynthesis during recovery from exercise in human skeletal muscle. NMR Biomed. 1993;6:66–72.
14.
ThompsonCHKempGJSandersonALRaddaGK. Skeletal muscle mitochondrial function studied by kinetic analysis of postexercise phosphocreatine resynthesis. J Appl Physiol. 1995;78:2131–2139.
15.
RodriguezMCMacDonaldJRMahoneyDJPariseGBealMFTarnopolskyMA. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve. 2007;35:235–242.
16.
FilipekPAJuranekJNguyenMTCummingsCGargusJJ. Relative carnitine deficiency in autism. J Autism Dev Disord. 2004;34:615–623.
17.
CorreiaCCoutinhoAMDiogoL. Brief report: High frequency of biochemical markers for mitochondrial dysfunction in autism: no association with the mitochondrial aspartate/glutamate carrier SLC25A12 gene. J Autism Dev Disord. 2006;36:1137–1140.
18.
LordCRutterMLe CouteurA. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord. 1994;24:659–685.
19.
LordCRisiSLambrechtL. The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord. 2000;30:205–223.
20.
EricksonLCScott-Van ZeelandAAHamiltonGLincolnAGolombBA. Brief report: approaches to (31)P-MRS in awake, non-sedated children with and without autism spectrum disorder. J Autism Dev Disord. 2012;42:1120–1126.
21.
VanhammeLvan den BoogaartAVan HuffelS. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson. 1997;129:35–43.
22.
NaressiACouturierCCastangIde BeerRGraveron-DemillyD. Java-based graphical user interface for MRUI, a software package for quantitation of in vivo/medical magnetic resonance spectroscopy signals. Comput Biol Med. 2001;31:269–286.
23.
HamiltonGPatelNFortonDMHajnalJVTaylor-RobinsonSD. Prior knowledge for time domain quantification of in vivo brain or liver 31P MR spectra. NMR Biomed. 2003;16:168–176.
24.
MurphyEJRajagopalanBBrindleKMRaddaGK. Phospholipid bilayer contribution to 31P NMR spectra in vivo. Magn Reson Med. 1989;12:282–289.
25.
HamiltonGAllsopJMPatelN. Variations due to analysis technique in intracellular pH measurements in simulated and in vivo 31P MR spectra of the human brain. J Magn Reson Imaging. 2006;23:459–464.
26.
PettegrewJWKeshavanMSPanchalingamK. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. Arch Gen Psychiatry. 1991;48:563–568.
BernierFPBonehADennettXChowCWClearyMA, Thorburn DR. Diagnostic criteria for respiratory chain disorders in adults and children. Neurology. 2002;59:1406–11.
30.
TaylorDJKempGJRaddaGK. Bioenergetics of skeletal muscle in mitochondrial myopathy. J Neurol Sci. 1994;127:198–206.
